At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
Albendazoledrug
Likely dose
Albendazole 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males
In Brief
A Phase 1 clinical trial evaluating Albendazole for Helminthiasis. Completed, enrolled 56 participants across 2 sites.
Detailed Summary
The purpose of the study is to compare the pharmacokinetic profiles of two Albendazole tablet formulations manufactured under the different granulation processes in healthy Chinese adult males.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHelminthiasis
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
Primary CompletionApr 2012
Study CompletionJun 2012
First PostedDec 2012
TodayJul 2026
First PostedDec 24, 2012
Enrollment StartApr 1, 2012
Primary CompletionApr 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 13.5 years ago
Interventions
Albendazoledrug
Albendazole tablets 400 mg